AER experiment gets OMB approval
This article was originally published in The Tan Sheet
Executive Summary
A proposed experiment by FDA's Center for Drug Evaluation and Research designed to identify statements that most effectively convey OTC and Rx AER data to consumers has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995, FDA announces. The agency proposed the experiment, "Toll-Free Number for Consumer Reporting of Drug Product Side Effects: Comprehension" following a proposed rule in 2004 requiring all OTCs approved under an NDA or ANDA to add a toll-free number and other statement to product labeling for AER purposes (1"The Tan Sheet" April 26, 2004, p. 14)...
You may also be interested in...
Industry Roundup: FDA Inspecting McNeil Plants, Hi-Tech Gets Another Chance Against FTC
J&J CFO Domnic Caruso says FDA officials are at McNeil’s three plants subject to a consent decree; an appeals court says a lower court should allow Hi-Tech to present additional evidence for weight loss claims.
Industry Roundup: FDA Inspecting McNeil Plants, Hi-Tech Gets Another Chance Against FTC
J&J CFO Domnic Caruso says FDA officials are at McNeil’s three plants subject to a consent decree; an appeals court says a lower court should allow Hi-Tech to present additional evidence for weight loss claims.
Toll-Free AER Number For Sec. 505 OTCs To Be On Labels One Year After Rule
FDA is planning to allow OTCs approved under an NDA or ANDA up to one year to add a toll-free number to labeling for adverse event reports, according to a 1proposed rule published in the April 22 Federal Register